1026 related articles for article (PubMed ID: 29550324)
1. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
3. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
[TBL] [Abstract][Full Text] [Related]
4. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
[TBL] [Abstract][Full Text] [Related]
5. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis.
Pan JA; Kerwin MJ; Salerno M
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1299-1310. PubMed ID: 32498919
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis.
Azevedo Coutinho MC; Cortez-Dias N; Cantinho G; Gonçalves S; Cunha N; Rodrigues T; Santos L; Conceição I; Agostinho J; Pinto FJ
Amyloid; 2024 Mar; 31(1):32-41. PubMed ID: 37493395
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.
Lin L; Li X; Feng J; Shen KN; Tian Z; Sun J; Mao YY; Cao J; Jin ZY; Li J; Selvanayagam JB; Wang YN
J Cardiovasc Magn Reson; 2018 Jan; 20(1):2. PubMed ID: 29298704
[TBL] [Abstract][Full Text] [Related]
9. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.
Bokhari S; Castaño A; Pozniakoff T; Deslisle S; Latif F; Maurer MS
Circ Cardiovasc Imaging; 2013 Mar; 6(2):195-201. PubMed ID: 23400849
[TBL] [Abstract][Full Text] [Related]
10. Myocardial Edema and Prognosis in Amyloidosis.
Kotecha T; Martinez-Naharro A; Treibel TA; Francis R; Nordin S; Abdel-Gadir A; Knight DS; Zumbo G; Rosmini S; Maestrini V; Bulluck H; Rakhit RD; Wechalekar AD; Gilbertson J; Sheppard MN; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2018 Jun; 71(25):2919-2931. PubMed ID: 29929616
[TBL] [Abstract][Full Text] [Related]
11. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
[TBL] [Abstract][Full Text] [Related]
12. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis.
Chamling B; Bietenbeck M; Drakos S; Korthals D; Vehof V; Stalling P; Meier C; Yilmaz A
Sci Rep; 2022 Dec; 12(1):21755. PubMed ID: 36526658
[TBL] [Abstract][Full Text] [Related]
13. Native T1 mapping in transthyretin amyloidosis.
Fontana M; Banypersad SM; Treibel TA; Maestrini V; Sado DM; White SK; Pica S; Castelletti S; Piechnik SK; Robson MD; Gilbertson JA; Rowczenio D; Hutt DF; Lachmann HJ; Wechalekar AD; Whelan CJ; Gillmore JD; Hawkins PN; Moon JC
JACC Cardiovasc Imaging; 2014 Feb; 7(2):157-65. PubMed ID: 24412190
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
15. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
[TBL] [Abstract][Full Text] [Related]
16. Routine 4D Cardiac CT to Identify Concomitant Transthyretin Amyloid Cardiomyopathy in Older Adults with Severe Aortic Stenosis.
Bernhard B; Leib Z; Dobner S; Demirel C; Caobelli F; Rominger A; Schütze J; Grogg H; Alwan L; Spano G; Boscolo Berto M; Lanz J; Pilgrim T; Windecker S; Stortecky S; Gräni C
Radiology; 2023 Dec; 309(3):e230425. PubMed ID: 38085082
[TBL] [Abstract][Full Text] [Related]
17.
Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
[TBL] [Abstract][Full Text] [Related]
18. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.
Baggiano A; Boldrini M; Martinez-Naharro A; Kotecha T; Petrie A; Rezk T; Gritti M; Quarta C; Knight DS; Wechalekar AD; Lachmann HJ; Perlini S; Pontone G; Moon JC; Kellman P; Gillmore JD; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):69-80. PubMed ID: 31202744
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
Briasoulis A; Lama N; Rempakos A; Theodorakakou F; Stamatelopoulos K; Dimopoulos MA; Kelekis N; Kastritis E
Curr Probl Cardiol; 2023 Apr; 48(4):101573. PubMed ID: 36586704
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
